The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product will be administered in this study. This study will enroll 120 participants with CALD treated with eli-cel in the post-marketing setting. A subpopulation of 24 participants with more advanced early active CALD will be specifically enrolled as required by the US FDA as a condition of accelerated approval and will be considered as a separate cohort for effectiveness outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants who Experience Each Individual Adverse Events of Interest (AEIs)
Timeframe: Through 15 years postinfusion
Number of Participants with Newly Diagnosed Malignancies
Timeframe: Through 15 years postinfusion
Number of Participants with Insertional Oncogenesis
Timeframe: Through 15 years postinfusion
Major Functional Disability (MFD)-Free Survival
Timeframe: Through 15 years postinfusion